We present two patients with central nervous system (CNS) disease associated with Sjögren's syndrome (SjS) and positive for antiaquaporin-4 water channel autoantibodies (AQP4-Ab) who were treated successfully with tacrolimus. Tacrolimus is an immunosuppressant that acts as a calcineurin inhibitor and suppresses T helper 2 (Th2) cells [1] . Tacrolimus may also act as a neuroprotectant by reducing axonal and myelin damage, as shown in a mouse model of experimental autoimmune encephalomyelitis [2] . SjS is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands. SjS-associated inflammation sometimes spreads into the CNS (CNS-SjS), occasionally mimics relapsing-remitting multiple sclerosis (MS), and inflammation often involves the brain, spinal cord, and optic nerve [3] . Neuromyelitis optica (NMO) is also a relapsing inflammatory disease of the CNS, characterized by severe attacks of optic nerve neuritis and longitudinally extensive transverse myelitis [4] . NMO is distinguished from MS by the presence of AQP4-Ab and differences in the distribution of inflammatory lesions and pathological findings. Combination therapy with a corticosteroid and azathioprine is the current standard treatment for preventing NMO relapse [5]; however, some patients are refractory to this therapy. Approximately 3% of patients with NMO have coexisting systemic lupus erythematosus (SLE) or SjS, and CNS-SjS patients with optic nerve neuritis or longitudinal myelitis (conditions called ''NMO spectrum disorder'') often present with positive findings for AQP4-Ab [4, 6, 7] . To our knowledge, this is the first reported assessment of tacrolimus in patients with CNS-SjS with AQP4-Ab. This treatment was approved by the ethical committee of our university, and the patients provided written informed consent.
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A 48-year-old female (Patient 1, Fig. 1 ) was admitted to the hospital with rapidly progressive nausea, hiccups, dysphagia, and drowsiness. Magnetic resonance imaging (MRI) revealed T2 hyperintensities of the hypothalamus bilaterally and the dorsal medulla oblongata. After three courses of intravenous high-dose methylprednisolone (IHMP, 1 g/day for 3 days in one course), the patient recovered completely, except for mild dysphagia. One year after the first attack, she developed limb weakness. Laboratory test results revealed high levels of anti-Ro (SSA) antibodies and positive antinuclear antibody. The Schirmer test and the Saxon test revealed decreased salivary secretion (Table 1) . She was diagnosed with CNS-SjS [8] . She experienced nine attacks during the entire disease course, and we started treatment with oral tacrolimus during her ninth admission. No recurrent attacks have been observed for 49 months since the start of this treatment.
A 50-year-old female (Patient 2) visited our hospital with acute left visual loss and depression. She was diagnosed with retrobulbar optic nerve neuritis, but she rejected steroid therapy and was not admitted to our hospital. One year later, she was sent to our hospital by ambulance due to weakness. Physical examination revealed dysphagia, dysarthria, incomplete tetraplegia, urinary retention, and depression. MRI revealed T2 hyperintensities in the corpus callosum, thalamus, midbrain, and pons. She was diagnosed with CNS-SjS based on SjS criteria (Table 1) , and she was treated with IHMP. Because high doses of oral steroids may exacerbate depression, we started therapy with tacrolimus (3 mg/day) to prevent relapse. No recurrence was observed for nine months, but she could not continue the therapy due to exacerbation of depression. Two years after withdrawal, she suffered right hemiplegia, and MRI revealed a relapse lesion in the left posterior limb of the internal capsule.
The serum of both patients was positive for AQP4-Ab after the initiation of tacrolimus. Because no recurrences were observed for at least 9 months for one patient (Patient 2) and 49 months for the other (Patient 1), we concluded that tacrolimus is effective in CNS-SjS with AQP4-Ab. Considering the pathological observations that indicate loss of AQP4 with deposition of antibody and compliment in CNS lesions in NMO [9, 10] , we speculate that tacrolimus may act by suppressing the humoral immunity against AQP4 through Th2 inhibition. 
